Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its presentation at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 ...

JPMorgan remains a “Buy” as strong fundamentals, raised EPS forecasts, and productivity gains from digital investments support bullish outlook.

Perrigo Company plc (NYSE:PRGO) is included among the Best Stocks for a Dividend Achievers List. On December 15, JPMorgan lowered its price target on Perrigo Company plc (NYSE:PRGO) to $18 from $20 ...

Regeneron is set for a turnaround as Dupixent and Libtayo drive growth, and 2026 pipeline catalysts may boost revenue. See why REGN stock is a strong buy.

JPMorgan raised the firm’s price target on CVS Health (CVS) to $101 from $93 and keeps an Overweight rating on the shares.